Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is an early-phase study testing ST-067, a new cancer immunotherapy drug. The study checks whether ST-067 is safe and shows signs of working in people with advanced solid tumors (cancers that form lumps in organs or tissues). The first phase focuses on safety; the second phase looks at effectiveness in specific cancer types. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of an advanced or metastatic solid tumor (such as melanoma, kidney cancer, lung cancer, bladder cancer, or others) - You are in reasonably good health overall (able to carry out daily activities) - You are willing to give informed consent **You may NOT be eligible if...** - Your cancer is not one of the approved tumor types for this trial - Your overall health status does not meet the study's fitness requirements - You have other conditions that would make participation unsafe Talk to your doctor to see if this trial is right for you.